RADIATION & RISK
Bulletin of the National Radiation and Epidemiological Registry
since 1992
About the Journal : 2007 : vol. 16, No. 2-4 : Estimation of exposure of metastatic foci and critical bone structures in the perfor-mance of radionuclide therapy with Sm-153-oxabifor

Estimation of exposure of metastatic foci and critical bone structures in the perfor-mance of radionuclide therapy with Sm-153-oxabifor

«Radiation and Risk», 2007, vol. 16, No. 2-4, pp.48-60

Authors

Dolya О.P.1, Klepov А.N.1, Кrylov V.V., Drozdovsky B.Ya., Маtusevich Е.S1, Oleinik N.А., Spichenkova О.N.
Medical Radiological Research Centre of RAMS, Obninsk.
1Obninsk State Technical University for Nuclear Power Engineering (IATE), Obninsk.

Abstract

Absorbed radiation doses to metastatic foci were estimated in 16 patients with bone metastases from different tumors, who received 153Sm-oxabifor injection (1.0 mCi/kg of body mass) for palliative treatment. The uptake rate for the radiopharmaceutical was estimated by relative accumulation of the radionuclide in the uptake foci. The conjugate view method was used to determine the activity of 153Sm. The gamma-camera sensitivity coefficients were obtained based on measurements of the activity of 153Sm standard sources. Absorbed doses to critical organs (red bone marrow and endosteal layer) were calculated using the adjusted MIRD methods, whereas doses to metastases were obtained with the homogenous structure model. The absorbed doses to metastatic foci were found to range from 2 to 91 Gy and the spread in the radiation doses to the critical organs was: [0.6÷1.7] Gy for red bone marrow, [2.0÷5.6] Gy for endosteal layer.

Key words
Absorbed doses in metastatic foci, domestic radiopharmaceutical, RFP 153Sm-oxabiphore, bone metastases, palliative treatment, radiation loads, bone marrow, endosteal bone.

References

1. Dolya O.P., Matusevich E.G., Klepov A.N. Experimental-calculation dosimetric studies in radionuclide therapy of patients with bone metastases. In Proc. Radiation protection and radionuclide safety in nuclear technologies. IX Russian Scientific Conference. Obninsk, 2006. PP. 400-402.

2. Krasnova E.V. Possibilities of strontium-89 chloride in complex therapy of bone metastases: Author's abstract. dis ... cand. med. sciences. Obninsk, 2006. 23 p.

3. Krylov V.V., Karyakin O.B., Drozdovsky B.Ya. Radionuclide therapy in the treatment of prostate cancer patients with bone metastases. Oncourology. 2006. No. 1. PP. 61-68.

4. Krylov V.V., Tsyb A.F., Drozdovsky B.Ya. Radionuclide therapy in palliative treatment of patients with bone metastases. Palliative Medicine and Rehabilitation. 2005. No. 3. PP. 40-47.

5. Basic sanitary rules for ensuring radiation safety (OSPROB-99). SP 2.6.1.799-99. Ministry of Health of Russia, 2000. 98 p.

6. The limits of radionuclide intake for workers with ionizing radiation. Publication 30 ICRP. Moscow, Energoizdat Publ., 1982.

7. Schemes of decay of radionuclides. Energy and intensity of radiation. ICRP Publication 38: in 2 parts. Part 2: Translation from English. Moscow, Energoatomizdat Publ., 1987.

8. Chissov V.I., Starinsky V.V., Petrova G.V. The state of oncological care for the population of Russia in 2004. M: FGU MNIO im. P.A. Herzen Roszdrava, 2005. 184 pp.

9. The scale of toxicity of antitumor therapy criteria CTC - NCIC. Vidal the Specialist. Reference book of the series "Oncology". Ed. AstraFarmServis, 2003. P. 455.

10. Bayoth J.Е., Macey D.J. et al. Dosimetry and Toxity of Samarium-153-EDTMF Administrated for Bone Pain Due to Skeletal Metastases. J. Nucl. Med. 1994. Vol. 35. PP. 63-69.

11. Breen S.L., Powe J.E., Porter A.T. Dose Estimation in Strontium-89 Radiatherapy of Metastatic Prostatic Carcinoma. J. Nucl. Med. 1992. Vol. 33, no. 7. PP. 1316-1323.

12. Eary J.F., Collins C., Stabin M. et al. Samarium-153-EDTMP Biodistribution and Dosimetry Estimation. J. Nucl. Med. 1993. Vol. 34, no. 7. PP. 1031-1036.

13. John C.P. Radiation Absorbed Dose Calculations for Samarium-153 EDTMP Localized in Bone. J. Nucl. Med 1991. Vol. 32, no. 5. PP. 840-844.

14. Loevinger R., Berman M.A. Schema for Absorbed Dose Calculations for Biologically-Distributed Radionuclides. MIRD Pamphlet No. 1. J. Nucl. Med. 1968. No. 1 (Suppl). PP. 7-14.

15. Samaratunga R.C., Thomas S.R., Hinnefeld J.D. et al. A Monte Carlo Simulation Model for Radiation Dose to Metastatic Skeletal Tumor from Rhenium-186(Sn)-HEDP. J. Nucl. Med. 1995. Vol. 36, no. 2. PP. 336-350.

16. SCINTI. Version 4. The basic software of the radiodiagnostic information processing system. 20939937.00001-01 34 01. Moscow, NPK "Gelmos" Publ., 1998. 71 p.

17. Serafini A.N., Kuker R.A., Fernandez G. et al. Evaluation of Sm-153 EDTMP as a Tumoricidal Agent in Prostate Cancer. World J. Nucl. Med. 2002. Vol. 1, Suppl 2. P. 136.

18. Siegel J.A., Stephen R.T., Stubbs J.B. et al. Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. MIRD Pamphlet No. 16. J. Nucl. Mod. 1999. Vol. 40, No. 2 (Suppl). PP. 37-61.

19. Silberstein Е.В., Buscombe J.R., Mс. Ewans A. et al. Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Society of nuclear medicine procedure guidelines manual. 2003, PP. 145-153.

20. Spiers F.W. Dose to Trabecular Bone from Internal Beta-Emiters. Brit. J. Radiol. 1978. Vol. 14, no. 6. PP. 537-538.

21. Spiers F.W., Beddoe A.H. Calculated Dose Factors for the Radiosensitive Tissues in Bone Irradiated by Surface-deposited Radionuclides. Phys. Med. Biol. 1978 Vol. 23, no. 3. PP. 481-494.

22. Turner J.H. Treatment of painful skeletal metastases. Alasbimn Journal Special Issue: 8-th World Congress of Nuclear Medicine, No. 17, Sept. 2002.

Full-text article (in Russian)